This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

28 Jul 2011

EMA Recommends Liver Cancer Drug

EMA recommends orphan drug designation for 4SC's resminostat to treat hepatocellular carcinoma.

German drug developer 4SC AG has announced that resminostat, a drug for the treatment of hepatocellular carcinoma – the most common form of liver cancer – has been recommended for approval by the European Medicines Agency.


The recommendation has been forwarded to the EU commission for the final approval and publication in the community register.


The news follows the recent orphan drug designation granted by the US Food and Drug Administration for the same programme.


4SC CEO Ulrich Dauer said that both designations "emphasise the importance of developing novel therapies in this indication in order to provide effective treatment options to patients suffering from this life-threatening disease".

Related News